Neuroplast B.V., is a Dutch medical biotechnology company specialized in regenerative medicine, focused on bringing high qualified autologous stem cell products to the global market environment addressing short track programs (from bench to bedside). Neuroplast’s headquarter and GMP production facility are embedded in the Brightlands Chemelot industrial society in Geleen, The Netherlands, employing a team of experts specialized in biobased regenerative and personalized medicine. Neuro-Cells is classified as an ATMP (Advanced Therapy Medicinal Product) tissue engineered product by the European Medicine Agency (EMA).
LipoCoat BV is a spin-off company of the University of Twente (MESA+ nanotechnology institute). The LipoCoat revolutionary coating technology -which has its origin in 2010- will make any (bio)material surface non-thrombogenic, non-fouling and resistant towards surface pollution of micro-organisms and proteins. The use of LipoCoat coatings can increase the performance, comfort and safety of medical devices or enhance research applications. In addition, we provide a service to tailor coating properties and functionality to meet your demand.
Novioscan, gevestigd op de Novio Tech Campus in Nijmegen, werkt sinds 2014 aan de ontwikkeling van draagbare echosensoren. Die ambitie is voortgekomen uit de klinische vraag naar een oplossing voor kinderen die niet voelen wanneer ze moeten plassen. Door moderne technologie te combineren met innovatief ondernemerschap, heeft Novioscan na vier jaar onderzoek en ontwikkeling de eerste draagbare blaassensor op de markt gebracht voor kinderen van zes tot twaalf jaar.
At IME we believe that our integral offering of groundbreaking competence in technology, equipment and process development can enable and realize the envisioned medical devices for our customers. We have developed superior electrospinning technologies which enable the production of medical implants with a nanostructure representing the human extracellular matrix in a reproducible and scalable manner. Implants produced with our technology have proven to repair, replace and restore tissues and organ structures in the human body. Multiple products manufactured using our technology are now either on the market or in clinical development.
MeshID is a trust-tech software company with a focus on solutions for the global trust and corporate services industry. MeshID blockchain-based solutions enable clients to achieve operational excellence by meeting their regulatory compliance requirements faster, and better, than before. We give corporations and their corporate service providers the tools they need to securely share trusted and verified Know-Your-Client information with each other. The company has its headquarters in Amsterdam, the Netherlands.
Eurekite’s activities are all focused on its core invention: Flexiramics®. It is a flexible pure ceramic fiber mat that is light and flexible like paper, but retains the main physiochemical properties of traditional ceramics. The most important properties of ceramics are heat resistance, electrical insulation and resistance to corrosion. However, ceramics are very inflexible, which limits their application possibilities. As a flexible ceramic, Flexiramics® therefore has a unique potential for application in numerous technical fields. Flexiramics® is superior to products offered by competitors because Eurekite offers customized solutions that perform much better than alternatives due to Flexiramics® unique properties.
Sencure is a company based in Enschede, the Netherlands and was founded in 2021. Originally, the company was named ItoM Medical, a division of the chip developer “Semiconductors Ideas to the Market (ItoM)”. This company brought two worlds together. Experienced, highly qualified chip designers from the semiconductor world and experts from the Medical Device world with a fascination for the measurement of electrophysiological parameters on the human body. Sencure develops chips that helps you measure electrophysiological parameters on the human body in innovative ways. The goal is to have as little influence on a patient’s daily life as possible, combined with a maximum impact on the patient’s life. We bridge the gap between compliance and the best solutions for wearable health.
Lumana verwacht in Q2 2021 een 2de nieuwe participatie toe te voegen aan haar portefeuille.
Vol enthousiasme begin je aan je zoektocht naar die perfecte investeerder. Neem contact met ons op en wie weet is Lumana de juiste match!